Chiou J F, Liang J A, Hsu W H, Wang J J, Ho S T, Kao A
Cancer Center, Department of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan.
Lung. 2003;181(5):267-73. doi: 10.1007/s00408-003-1029-7.
Our aim was to compare Taxol-based chemotherapy response of non-small cell lung cancer (NSCLC) with P-glycoprotein (Pgp) or lung resistance protein expression (LRP). Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to detect Pgp and LPR expressions in 40 patients with advanced NSCLC before Taxol-based chemotherapy. The chemotherapy response was evaluated by clinical and radiological methods in the third month after completion of treatment. No significant differences of prognostic factors (age, sex, body weight loss, performance status, tumor size, tumor stage, and tumor cell type) were found between the 20 patients with good and the 20 patients with poor responses. The incidence difference of positive Pgp expressions between good and poor responses was significant, however, the difference of LRP expression was not. We concluded that Taxol-based chemotherapy response of patients with NSCLC was related to Pgp but not LPR expression.
我们的目的是比较非小细胞肺癌(NSCLC)基于紫杉醇的化疗反应与P-糖蛋白(Pgp)或肺耐药蛋白表达(LRP)之间的关系。对活检标本的多个非连续切片进行免疫组化分析,以检测40例晚期NSCLC患者在基于紫杉醇的化疗前的Pgp和LPR表达。在治疗完成后的第三个月,通过临床和影像学方法评估化疗反应。在化疗反应良好的20例患者和化疗反应不佳的20例患者之间,未发现预后因素(年龄、性别、体重减轻、体能状态、肿瘤大小、肿瘤分期和肿瘤细胞类型)存在显著差异。然而,化疗反应良好与不佳的患者之间Pgp阳性表达的发生率差异显著,而LRP表达的差异不显著。我们得出结论,NSCLC患者基于紫杉醇的化疗反应与Pgp有关,而与LPR表达无关。